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The  eradication  of infectious  agents  is an attractive  means  of  disease  control  that,  to date,  has  been
achieved  for  only  one  human  pathogen,  the  smallpox  virus.  The  introduction  of  vaccines  against  Neis-
seria  meningitidis  into  immunisation  schedules,  and  particularly  the  conjugate  polysaccharide  vaccines
which  can  interrupt  transmission,  raises  the  question  of  whether  disease  caused  by  this  obligate  human
bacterium  can  be  controlled,  eliminated,  or even  eradicated.  The  limited  number  of meningococcaleywords:
eisseria meningitidis
accines
pidemiology
opulation biology
serogroups,  lack  of an  animal  reservoir,  and  importance  of  meningococcal  disease  are  considerations  in
favour  of eradication;  however,  the  commensal  nature  of most  infections,  the  high  diversity  of  meningo-
coccal  populations,  and the  lack  of comprehensive  vaccines  are  all  factors  that  suggest that  this  is  not
feasible.  Indeed,  any  such  attempt  might  be  harmful  by  perturbing  the  human  microbiome  and  its inter-
action  with  the  immune  system.  On  balance,  the  control  and  possible  elimination  of disease  caused  by
particular  disease-associated  meningococcal  genotypes  is  a more  achievable  and  worthwhile  goal.. The control, eradication, and elimination of infectious
iseases
Throughout history infectious diseases have emerged as a con-
equence of the ways that human populations have changed their
cology. Before the acceptance of the germ theory of disease, the
apacity of human beings to react to these diseases was very lim-
ted, but over the last 120 years or so we have become increasingly
ble to anticipate the spread of diseases and make deliberate eco-
ogical interventions to prevent them or reduce their impact [1].
hilst many of these interventions have been spectacularly suc-
essful and made urban living both possible and even pleasant, the
ltimate goal of eradicating an infectious disease has been achieved
n only one case, that of smallpox. The reasons for the success of
his campaign, now over 30 years ago, are still instructive: small
ox was antigenically stable; infection and immunisation both gave
ifelong protection; there was no animal reservoir and no asymp-
omatic carrier state in humans; a safe universal vaccine that could
e produced and delivered world-wide was available; and there
as a strong political and public will to combat this terrible and
ebilitating disease [2]. The difﬁculties encountered by subsequent
ttempts to eradicate other diseases reﬂect the fact that none of
hem have met  all of these criteria [3].
The Dahlem workshop deﬁned a hierarchy of ﬁve levels of
ontaining infectious diseases: control; elimination of disease;
∗ Corresponding author. Tel.: +44 1865 271284; fax: +44 1865 281275.
E-mail  address: martin.maiden@zoo.ox.ac.uk (M.C.J. Maiden).
264-410X/© 2011 Elsevier Ltd.  
oi:10.1016/j.vaccine.2011.12.068
Open access under CC BY license.© 2011 Elsevier Ltd. 
elimination of infections; eradication; and extinction (Table 1) [4].
As novel vaccines are developed against pathogens it is appropriate
to examine the level in this hierarchy that can be achieved. There
is a natural desire to employ these new products to eliminate or
eradicate the disease in question. Here we will examine this ques-
tion for Neisseria meningitidis, the meningococcus, in the light of
the vaccines currently being developed and deployed against this
encapsulated bacterium [5]. As the most effective of these vaccines
target the asymptomatic carriage and transmission of meningo-
cocci among individuals [6], the question of whether elimination or
eradication can be achieved arises. Clearly, the best way to prevent
an infectious disease is to stop the circulation of the causative agent
and indeed drive it to extinction: if the pathogen is not present it
cannot cause pathology. In the case of the meningococcus, which is
an important cause of septicaemia and meningitis world-wide [7],
there are historical hints of a meningococcal disease-free world in
that this very distinctive disease was not conclusively described
before 1805 in Europe [8] and only towards the end of the 19th
century in sub-Saharan Africa [9]. Is it possible to return to this
desirable state? If this course is to be considered, it is necessary to
examine its feasibility and consequences in the light of the biology
of this intriguing organism.
2.  Meningococcal biology
Open access under CC BY license.The  meningococcus is only known to inhabit the human
nasopharynx, if one discounts its occasional isolation from the
human urogenital tract – the niche for its close relative the gono-
coccus [10]. It is asymptomatically carried in all human populations
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Table 1
The  Dahlem workshop deﬁnitions of public health interventions and examples.
Hierarchy of Intervention Deﬁnition Example
Control The reduction of disease incidence, prevalence, morbidity or mortality to a locally acceptable level
as  a result of deliberate efforts; continued intervention measures are required to maintain the
reduction
Diarrhoeal diseases
Elimination  of disease Reduction to zero of the incidence of a speciﬁed disease in a deﬁned geographical area as a result
of  deliberate efforts; continued intervention methods are required
Neonatal tetanus
Elimination  of infections Reduction to zero of the incidence of infection caused by a speciﬁc agent in a deﬁned geographical
area  as a result of deliberate efforts; continued measures to prevent reestablishment of
transmission are required
Measles, Poliomyelitis
Eradication Permanent reduction to zero of the worldwide incidence of infection caused by a speciﬁc agent as
asure
Smallpox
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Extinction  The speciﬁc infectious agent no longer exists
xamined to date, albeit at variable prevalence [11,12]. Further, it
as not been isolated from other animals and no known animal
eservoir exists [10]. Carriage, which is rare in infants, increases
ith age and is episodic: an individual will acquire a particular
eningococcus, carry that meningococcus for a period of time,
hich may  range from days to years, and then clear the infection
 remaining susceptible to infection by another meningococcus
13,14]. It is not known why some episodes of carriage develop into
isease, especially as this is unproductive for the bacterium as inva-
ion of the bloodstream, CSF, and meninges cannot lead to onward
ransmission [15]. Meningococcal disease should regarded as a dys-
unctional relationship which harms the host and, ultimately, also
he bacterium [16].
Some  of the answers to the paradox of a commensal causing
isease in a way that does not promote its own spread may  lie
n the extremely high diversity of this bacterium [16]. N. menin-
itidis possesses multiple mechanisms for generating antigenic
ariants by altering the levels of expression of multiple genes
17,18]. Presumably this aids interaction with a wide variety of
uman receptors for the purposes of colonisation and for the eva-
ion of immune responses [19]. In addition to this intra-strain
iversity, meningococci are highly diverse at the population level,
ith many thousands of distinct genotypes identiﬁed by various
olecular typing methods, many generated by frequent genetic
xchange among these highly transformable organisms [20]. This
ontinual within and among-host evolution is likely to occasionally
enerate variants that are more likely to cause disease; however,
ostly these are maladaptive and will not spread beyond the host
n which they arise. One body of theory suggests that it is only
ildly pathogenic variants that spread to cause large outbreaks,
s they incur only a small cost for their pathogenicity [21]. In any
ase, it is likely: (i) that particular cell components have ambiguous
olls, promoting asymptomatic transmission but also increasing
he likelihood of causing disease; and, (ii) that different circulat-
ng genotypes are a consequence of evolutionary forces that act
o balance transmission efﬁciency against their likelihood to cause
nvasive disease [22].
In  common with the great majority of bacteria that inhabit the
asopharynx, most meningococci present no risk to human health
 a substantial proportion of meningococci possess no capsular
ocus [23], and only six of the 12 capsular serogroups are associ-
ted with disease, with ﬁve of these, serogroups A, B C, W and Y,
esponsible for most cases of invasive disease [24]. Multiple distinct
enotypes exist which can be identiﬁed by multilocus sequence
yping (MLST) as sequence types, which can be grouped into clonal
omplexes [25]. These are stable over decades and during global
pread, but only a small number of them – the so-called ‘hyper-
nvasive lineages’ – cause most invasive disease [16]. The genetic
actors responsible for the hyperinvasive phenotype are incom-
letely understood: although virtually all invasive meningococcal
solates have a polysaccharide capsule, and a number of other geness are no longer needed
ure or the laboratory None
and  gene products have been implicated in invasion [15]. The role
of most of these is much more ambiguous, as none are found in
all invasive meningococci, and many are shared with less invasive
meningococci and other members of the genus Neisseria that do not
cause invasive infections [26–28].
The meningococcus thus represents a common member of the
microbiota of the human nasopharynx which rarely causes dis-
ease. Even in the case of the hyperinvasive meningococci, most
episodes of carriage are asymptomatic [29]. It is likely that car-
riage of these organisms has some beneﬁt to the host, even if this
is only preventing other more pathogenic bacteria occupying the
same niche. Carriage of the close relative of the meningococcus,
the acapsulate Neisseria lactamica, for example, is very common in
infants but invasive disease cause by this bacterium is extraordi-
narily rare [30]. Almost certainly the carriage of these organisms
results in the development of an immune response and, as individ-
uals age, they acquire immunity against invasion from carriage [31].
Hence, in planning public health interventions that target meningo-
cocci by affecting the carrier state, it is necessary to consider (i)
which meningococci to target and (ii) the broader implications of
removing meningococci from carriage, as this may perturb natural
immunity.
2.1. Why  would we want to eradicate the meningococcus?
From the perspective of the clinician, especially the paediatri-
cian, the eradication of the meningococcus is a highly attractive
concept [32]. Meningococcal disease is a sudden onset and very
severe syndrome, principally affecting the very young, and an
infected individual can deteriorate from being apparently perfectly
healthy to presenting a medical emergency in a matter of a few
hours. Even in countries with access to state-of-the-art medical
facilities children still die when the race between diagnosis and
treatment and bacterial growth in the blood stream and/or cere-
bro spinal ﬂuid and is lost [33]. Individuals who survive frequently
suffer debilitating sequelae, further magnifying the impact of this
much-feared disease, even when disease rates are relatively low
[34]. In resource poor settings, the impact of the disease is even
greater, especially the meningitis belt of Africa, which experiences
large-scale epidemic outbreaks of meningococcal meningitis [9].
These outbreaks represent the highest burden of meningococcal
disease worldwide. They occur periodically, slightly more often
than once a decade, over a period of 5–6 weeks in the dry sea-
son during the period of the trade wind, the Harmattan. In addition
to causing tens of thousands of case and hundreds or thousands of
deaths, these outbreaks are very disruptive, overwhelming health-
care systems for their duration [35].2.2. What level of disease control is feasible?
On the balance of the evidence currently available, the erad-
ication of the meningococcus per se is not desirable, even if it
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ere achievable, which appears unlikely with current or foresee-
ble technology. As most infections with the meningococcus are
armless to the human host, deliberately removing a common
omponent of the commensal microbiota could have consequences
hat are not easily anticipated, for example the exploitation of the
acated niche by other, more harmful, organisms leading to the
ncrease similar or different pathologies. A further risk of target-
ng all meningococci indiscriminately is that this may  well be only
artially successful and could lead to the elimination of normally
armless meningococci, resulting in the paradoxical rise in disease
s passive and active protection accorded to the host population by
he carriage of these organisms is lost. Indiscriminate intervention
n a system that we do not understand is unwise.
Public health interventions are more appropriately targeted
o the control of the disease, rather than the eradication of the
eningococcal population as a whole. This is a much more achiev-
ble goal, with fewer possible negative consequences. As the great
ajority of invasive meningococci are encapsulated, with most
isease caused by a few serogroups, only bacteria expressing
hese capsular polysaccharides need be targeted. It is tempting
o speculate that the pre-disease era was a time when fewer
arried meningococci were encapsulated, at least with the disease-
ssociated capsular serogroups. Tools for tackling meningococci
hat express four of the disease-associated seogroups (A, C, Y and
) are to hand in the form of protein-conjugate polysaccharide
accines [5]. At least in the case of the meningococcal C polysac-
haride conjugate (MCC) vaccines, immunisation of the population
n which transmission is occurring can disrupt transmission to the
xtent that the circulation of potentially invasive organisms can be
educed to a very low level, if not completely eradicated [36,37].
n a number of countries this has been achieved for serogroup C
eningococci, with little convincing evidence of the replacement of
hese organisms with other harmful meningococci. The goal would
e to eliminate serogroup A, B, C, W,  Y, and perhaps X capsules:
ore speciﬁcally this means removing from the meningococcal
opulation the Region A variants of the cps genome region which
ncode the synthesis genes for these serogroups [38].
.3.  A strategy for the control or elimination of disease-associated
eningococci
A three-phase programme for the control or elimination of inva-
ive meningococci can be envisaged:
Phase I would target serogroup A and serogroup C meningococci
at  the global level. Effective conjugate vaccines exist against these
organisms,  including the recently introduced MenAfriVac vaccine
[39],  developed to be affordable in sub-Saharan countries [40].
Phase  II would target serogroup Y, W and X meningococci with
affordable  conjugate vaccines against these organisms. Vaccines
against  serogroups Y and W exist [41], and it is likely that a sero-
goup  X vaccine could be developed, although the disease burden
of  this serogroup remains limited [42]. There may be some cross-
protection  against strains expressing serogroup X by protein based
vaccines  developed against serogroup B meningococci. The ideal
solution  would be a ﬁve-valent conjugate polysaccharide vaccine
(A,  C, W,  X, Y), which was effective against these serogroups and
in  both disease and carriage.
Phase  III would target serogroup B, but this is much more prob-
lematic.  There is no conjugate polysaccharide vaccine available
against  this serogroup, and little prospect of one being developed
[43].  This phase, which would be important to ensure that the
current  burden of disease is not simply replaced by an increase in
serogroup B disease, therefore relies on a successful research and
development program to develop a broadly protective ‘serogroup
B  substitute’ vaccine.ine 30S (2012) B52– B56
3.  Can this strategy be realised?
Phases I and II are feasible with current technology, if chal-
lenging from a logistical point of view. Indeed, in one of the
most exciting developments in the history of meningococcal dis-
ease control, the rollout of the MenAfriVac conjugate serogroup
A polysaccharide vaccine presents the prospect of the end of epi-
demic group A meningococcal disease in sub-Saharan Africa [35].
The goal of the Meningitis Vaccine Project (MVP) was the sus-
tainable introduction of a serogroup A conjugate polysaccharide
vaccine, with the vaccine priced a less 1US$ per dose, a goal that
was achieved by a novel North–South partnership of technology
transfer and manufacturing capacity [40]. Other factors aiding the
elimination of serogroup A meningococci is their relative lack of
genetic diversity and geographical distribution. Virtually all cases
of serogroup A disease are caused by one of three clonal complexes,
ST-1 complex and the closely related ST-4 and ST-5 clonal com-
plexes [44]. This is different from sialic acid-containing serogroups
B, C, W and Y which are found in numerous genetically divergent
clonal complexes. Similarly, whilst the sialic acid capsules are glob-
ally distributed, much of the serogroup A disease is in Africa and
Asia [9,44,45], with certain regions currently experiencing little or
no serogroup A disease [16]. After Africa, therefore a major effort of
introduction of MenAfriVac into Asia could see a dramatic reduction
in the disease burden of group A meningococci, perhaps resulting
in the elimination of this disease globally and perhaps even the
eradication of group A meningococci [35].
Similar arguments can be made for the MCC  vaccines, which
have achieved virtual eradication of serogroup C meningococcal
disease in a number of countries where it has been introduced
[46]. It should be noted here that it is more accurate to say that
serogroup C ST-11 complex meningococci, which express their cap-
sules at high rates, have been eradicated [37]. It is possible that
other genotypes which express the capsule at lower rates, and are
consequently less susceptible MCC  vaccines, could act as a reservoir
for the genes encoding the serogroup C capsule, making its eradica-
tion difﬁcult. A further problem is that meningococci that express
this capsule are globally distributed [16], including in countries
that have low incidence rates of disease, which might be resis-
tant to the universal introduction of a vaccine against an organism
which represents only a modest threat to their public health –
evidence for this is the patchy introduction of this vaccine in Euro-
pean counties. Those countries which have immunised children
and young adults with MCC  vaccines, such as the United Kingdom
and the Netherlands, have exhibited the most dramatic reductions
in serogroup C disease [36,47].
Compared  with Phase I, Phase II presents a number of uncer-
tainties. Serogroups W and, particularly, Y are less common causes
of disease and are commonly carried. In addition they are found
in a range of clonal complexes, a number of which very rarely
cause disease and their rates of capsule expression during carriage
are lower, ranging from 28 to 70%, depending on the clonal com-
plex [29,48]. Experience from the UK MCC  introduction suggests
that it was the high rate of capsule expression in carriage, com-
bined with genetic uniformity of the ST-11 complex serogroup C
meningococci, which resulted in the high impact of the vaccine [37].
Extrapolating this success to other serogroups, especially Y and
W may  well be optimistic. More worryingly, the apparently very
low invasive potential of serogroup Y ST-22 complex meningococci
[29], suggests that their elimination may  be detrimental to dis-
ease control, at least whilst other more invasive meningococci are
still circulating. Very high rates of serogroup Y carriage have been
reported and, whilst these have been associated with increases in
rates of serogroup Y disease, these remain very low compared with
the disease rates that occur during periods of elevated transmission
of hyperinvasive serogroup B and C meningococci [29]. It is at least
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ossible the serogroup Y organisms prevent disease by excluding
ore harmful organisms and attempting their elimination must
ake this into account. Further, the low levels of capsule expres-
ion of some clonal complexes associated with serogroup Y during
arriage [48] may  render their elimination impossible with current
pproaches.
Phase III – the elimination of serogroup B meningococci, is by
ar the most challenging goal both from the perspective of the tools
urrently available and the biology of the meningococcus [5,43].
he ﬁrst, and by far the most serious problem, is that the develop-
ent of a conjugate vaccine against the serogroup B polysaccharide
s precluded by a combination of the poor immunogenicity of this
olysaccharide and safety concerns, as it is identical to a host anti-
en NCAM, which decorates foetal neural tissues [49]. Further, a
umber of quite different clonal complexes that express serogroup
 have been associated with disease and over the last decades
everal have emerged and spread globally in succession [16]. To
ate, all of the ‘serogroup B substitute’ vaccines that have been
mplemented have been based on the proteins expressed on the
urface of a particular meningococcal strain [50–52]. These pro-
ide protection against disease caused by that strain and close
elatives, i.e. members of the same clonal complex that express
imilar antigenic variants, but not against others [53]. More sophis-
icated formulations that increase the coverage against serogroup
 meningococci are being aggressively developed [54,55]. It will be
nteresting to learn whether these vaccines will be able to interrupt
ransmission to the extent that eradication or elimination would be
ossible.
. Conclusion
The eradication of all carried meningococci is almost certainly
either achievable nor desirable: the control, elimination, or erad-
cation of particular invasive meningococci is a more realistic goal,
iven that a limited number of clonal complexes and serogroups
ause most meningococcal disease. However, even this goal is
ikely to be difﬁcult and requires more research and great politi-
al will to achieve. In terms of practicability and desirability, the
enaAfriVac vaccine and its introduction indicates how epidemic
erogroup A disease can potentially be eliminated or eradicated.
he other serogroups are more problematic. Serogroup C is the
ext most likely candidate, although the biology and logistics are
ess favourable than for serogroup A. Serogroups Y and W could
e targeted, but the cost beneﬁt of this is less clear at the current
ime. In principle a serogroup X vaccine could be developed, but
hether the disease burden is sufﬁcient to warrant its introduc-
ion at a scale sufﬁcient for eradication of group X meningococci is
oubtful. Finally, and perhaps most problematically, no tools cur-
ently exist for controlling serogroup B meningococci per se, and
lthough it may  be possible to develop vaccines that target particu-
ar or even most serogroup B-associated clonal complexes, thereby
ubstantially reducing disease burden, eradicating all group B
eningococci from carriage globally is unlikely to be feasible.
onsequently, a world free of invasive meningococci remains an
lluring but still distant prospect, although a world with apprecia-
ly less meningococcal disease is an achievable and worthwhile
oal in the immediate future.
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